Neoantigen Cancer Vaccine Market Report

Global and Region Neoantigen Cancer Vaccine Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：193
  • REPORT CODE：GMM1021433
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neoantigen Cancer Vaccine market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neoantigen Cancer Vaccinemarket, defines the market attractiveness level of Neoantigen Cancer Vaccine market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neoantigen Cancer Vaccine industry, describes the types of Neoantigen Cancer Vaccine market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neoantigen Cancer Vaccine market and the development prospects and opportunities of Neoantigen Cancer Vaccine industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neoantigen Cancer Vaccine market in Chapter 13.

    By Player:

    • Genocea

    • OSE Immunotherapeutics

    • Medimmune

    • Gritstone Oncology

    • Brightpath Biotherapeutics

    • Agenus

    • Roche

    • Nouscom

    • Medigene

    • Vaccibody

    • Geneos Therapeutics

    • Neon Therapeutics

    • Merck

    • Advaxis

    By Type:

    • Personalized Vaccine

    • Off-the-shelf Neovaccines

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neoantigen Cancer Vaccine Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neoantigen Cancer Vaccine Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neoantigen Cancer Vaccine Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neoantigen Cancer Vaccine Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neoantigen Cancer Vaccine Market Analysis and Outlook to 2022

    • 7.1 Global Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.2 United States Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.3 Europe Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.4 China Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.5 Japan Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.6 India Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 7.7 South Korea Neoantigen Cancer Vaccine Consumption (2017-2022)

    8 Region and Country-wise Neoantigen Cancer Vaccine Market Analysis and Outlook to 2028

    • 8.1 Global Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.2 United States Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.3 Europe Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.4 China Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.5 Japan Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.6 India Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 8.7 South Korea Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    9 Global Neoantigen Cancer Vaccine Market Outlook by Types and Applications to 2022

    • 9.1 Global Neoantigen Cancer Vaccine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Personalized Vaccine Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Off-the-shelf Neovaccines Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neoantigen Cancer Vaccine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Neoantigen Cancer Vaccine Market Outlook by Types and Applications to 2028

    • 10.1 Global Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Personalized Vaccine Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Off-the-shelf Neovaccines Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neoantigen Cancer Vaccine Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neoantigen Cancer Vaccine Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neoantigen Cancer Vaccine Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neoantigen Cancer Vaccine Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neoantigen Cancer Vaccine Market Competitive Analysis

    • 14.1 Genocea

      • 14.1.1 Genocea Company Details

      • 14.1.2 Genocea Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Genocea Neoantigen Cancer Vaccine Product and Service

    • 14.2 OSE Immunotherapeutics

      • 14.2.1 OSE Immunotherapeutics Company Details

      • 14.2.2 OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Product and Service

    • 14.3 Medimmune

      • 14.3.1 Medimmune Company Details

      • 14.3.2 Medimmune Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Medimmune Neoantigen Cancer Vaccine Product and Service

    • 14.4 Gritstone Oncology

      • 14.4.1 Gritstone Oncology Company Details

      • 14.4.2 Gritstone Oncology Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Gritstone Oncology Neoantigen Cancer Vaccine Product and Service

    • 14.5 Brightpath Biotherapeutics

      • 14.5.1 Brightpath Biotherapeutics Company Details

      • 14.5.2 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product and Service

    • 14.6 Agenus

      • 14.6.1 Agenus Company Details

      • 14.6.2 Agenus Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Agenus Neoantigen Cancer Vaccine Product and Service

    • 14.7 Roche

      • 14.7.1 Roche Company Details

      • 14.7.2 Roche Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Roche Neoantigen Cancer Vaccine Product and Service

    • 14.8 Nouscom

      • 14.8.1 Nouscom Company Details

      • 14.8.2 Nouscom Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Nouscom Neoantigen Cancer Vaccine Product and Service

    • 14.9 Medigene

      • 14.9.1 Medigene Company Details

      • 14.9.2 Medigene Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Medigene Neoantigen Cancer Vaccine Product and Service

    • 14.10 Vaccibody

      • 14.10.1 Vaccibody Company Details

      • 14.10.2 Vaccibody Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Vaccibody Neoantigen Cancer Vaccine Product and Service

    • 14.11 Geneos Therapeutics

      • 14.11.1 Geneos Therapeutics Company Details

      • 14.11.2 Geneos Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Geneos Therapeutics Neoantigen Cancer Vaccine Product and Service

    • 14.12 Neon Therapeutics

      • 14.12.1 Neon Therapeutics Company Details

      • 14.12.2 Neon Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Neon Therapeutics Neoantigen Cancer Vaccine Product and Service

    • 14.13 Merck

      • 14.13.1 Merck Company Details

      • 14.13.2 Merck Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Merck Neoantigen Cancer Vaccine Product and Service

    • 14.14 Advaxis

      • 14.14.1 Advaxis Company Details

      • 14.14.2 Advaxis Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Advaxis Neoantigen Cancer Vaccine Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neoantigen Cancer Vaccine

    • Figure Neoantigen Cancer Vaccine Picture

    • Table Global Neoantigen Cancer Vaccine Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neoantigen Cancer Vaccine Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neoantigen Cancer Vaccine Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure United States Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table Europe Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure China Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Japan Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure India Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Global Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure United States Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Personalized Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Global Off-the-shelf Neovaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Personalized Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Off-the-shelf Neovaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neoantigen Cancer Vaccine Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neoantigen Cancer Vaccine Export by Region (Top 5 Countries) (2017-2028)

    • Table Genocea (Foundation Year, Company Profile and etc.)

    • Table Genocea Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genocea Neoantigen Cancer Vaccine Product and Service

    • Table OSE Immunotherapeutics (Foundation Year, Company Profile and etc.)

    • Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Product and Service

    • Table Medimmune (Foundation Year, Company Profile and etc.)

    • Table Medimmune Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Medimmune Neoantigen Cancer Vaccine Product and Service

    • Table Gritstone Oncology (Foundation Year, Company Profile and etc.)

    • Table Gritstone Oncology Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gritstone Oncology Neoantigen Cancer Vaccine Product and Service

    • Table Brightpath Biotherapeutics (Foundation Year, Company Profile and etc.)

    • Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product and Service

    • Table Agenus (Foundation Year, Company Profile and etc.)

    • Table Agenus Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Agenus Neoantigen Cancer Vaccine Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Neoantigen Cancer Vaccine Product and Service

    • Table Nouscom (Foundation Year, Company Profile and etc.)

    • Table Nouscom Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nouscom Neoantigen Cancer Vaccine Product and Service

    • Table Medigene (Foundation Year, Company Profile and etc.)

    • Table Medigene Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Medigene Neoantigen Cancer Vaccine Product and Service

    • Table Vaccibody (Foundation Year, Company Profile and etc.)

    • Table Vaccibody Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vaccibody Neoantigen Cancer Vaccine Product and Service

    • Table Geneos Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Geneos Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Geneos Therapeutics Neoantigen Cancer Vaccine Product and Service

    • Table Neon Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Neon Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neon Therapeutics Neoantigen Cancer Vaccine Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Neoantigen Cancer Vaccine Product and Service

    • Table Advaxis (Foundation Year, Company Profile and etc.)

    • Table Advaxis Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Advaxis Neoantigen Cancer Vaccine Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US